Earnings Insights · MRNA · Q3 FY2026
Moderna Q3 2026 Earnings: Raised Revenue Outlook as COVID Sales and Cost Cuts Restore Profitability
By AlgovestIQ ResearchPublished
Read Moderna’s results announcement (Form 8-K, filed Nov 6, 2026)
Key earnings findings
Moderna (MRNA) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Moderna reported Q3 FY2026 revenue of $1.31B against the $890.3M analyst estimate, a 47.5% beat, and EPS of $0.38 against the -$1.10 analyst estimate.
- The company raised its 2026 revenue-growth outlook to 15% to 25% from a prior expectation of up to 10%, reflecting stronger-than-expected COVID vaccine demand and execution in both U.S. and international markets.
- MRNA closed at $254.19 on Nov 6, 2026, up 5.3% from $241.46 on Nov 5, 2026, the last close before the results were released.
Sources: Moderna results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Moderna beat earnings expectations?
- EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
- Revenue surprise across the last 8 reported quarters has ranged from -84.1% to 64.6%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Moderna reported third-quarter revenue of $1.3B, up 29% year over year, and GAAP diluted EPS of $0.38, compared with a loss of $0.51 per share a year earlier. The company raised its 2026 revenue-growth outlook to 15% to 25% from a prior expectation of up to 10%, reflecting stronger-than-expected COVID vaccine demand and execution in both U.S. and international markets.
The quarter also marked a strategic shift beyond respiratory vaccines. Positive Phase 3 melanoma data for intismeran autogene strengthened Moderna’s oncology opportunity, while a $3.0B convertible-note offering improved liquidity but added a sizable new debt obligation.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $1.3B | Up 29% year over year |
| Net product sales | $1.3B | Up 31% year over year |
| U.S. revenue | $780M | — |
| International revenue | $533M | — |
| Cost of sales | $318M | Up 54% year over year |
| Research and development expense | $583M | Down 27% year over year |
| Selling, general and administrative expense | $282M | Up 5% year over year |
| GAAP operating income | $130M | Versus $(260)M loss |
| GAAP net income | $162M | Versus $(200)M loss |
| GAAP diluted EPS | $0.38 | Versus $(0.51) loss per share |
| Cash, cash equivalents and investments | $8.0B | Up from $6.9B at June 30, 2026 |
| Nine-month operating cash flow | $(2.7)B | Versus $(2.8)B used |
The Bigger Story
Moderna’s financial improvement was driven primarily by a better-than-expected COVID vaccine season and lower development spending, rather than a broad revenue contribution from its newer products. Net product sales reached $1.3B in the quarter, with higher international COVID vaccine sales, including deliveries under long-term government partnerships, accounting for most of the increase.
The raised full-year growth outlook is notable because Moderna had entered 2026 expecting only modest growth. Management said both U.S. and international markets exceeded internal expectations, aided by mNEXSPIKE adoption in the United States, stable vaccination rates, and execution in strategic partnership markets including the United Kingdom, Canada and Australia.
Still, the company’s longer-term diversification remains early. mFLUSIVA, its seasonal influenza vaccine, was approved in the United States only after the annual contracting cycle and is being launched on a limited basis for the 2026-2027 flu season. Management described flu revenue as relatively immaterial in 2026. The immediate commercial story therefore remains heavily dependent on COVID vaccine sales and international government arrangements.
The more consequential change to the investment case is clinical. Intismeran, Moderna’s individualized cancer therapy developed with Merck, produced positive Phase 3 data in resected high-risk melanoma. The companies are preparing regulatory submissions, and management said it is targeting a biologics license application submission this year, with a potential approval next year if the process proceeds as expected.
Revenue and Operating Performance
Third-quarter revenue was $1.313B, including $1.273B in product sales and $40M in other revenue. Revenue increased from $1.016B a year earlier, with product sales accounting for nearly all of the growth.
The geographic mix was weighted toward the United States, where revenue was $780M, versus $533M internationally. Management said stronger U.S. performance reflected increased mNEXSPIKE uptake and relatively stable seasonal vaccination rates. International performance benefited from strategic government partnerships and commercial execution, particularly in the United Kingdom and Canada.
International revenue has become a more meaningful part of Moderna’s commercial base. Management said year-to-date international revenue had reached $900M, already $200M above the full-year level achieved in 2025. It also said more than half of international revenue is tied to strategic partnerships, which could provide more durability than purely seasonal, discretionary vaccine demand.
However, timing also contributed to the third-quarter result. Management cited shipment timing between the third and fourth quarters as one of the drivers of revenue that exceeded expectations. That means investors should be cautious about treating the quarter’s growth rate as a direct indicator of underlying annual demand.
Moderna continued to expand its respiratory portfolio. The FDA approved mFLUSIVA for adults aged 50 to 64 and granted accelerated approval for adults 65 and older. Canada also approved mFLUSIVA, while Moderna’s flu/COVID combination vaccine, mCOMBRIAX, has approvals in Canada and the European Union. U.S. regulatory timing for the combination product remains uncertain, as Moderna is awaiting further FDA guidance before refiling.
Profitability and Margins
Moderna returned to quarterly GAAP profitability, reporting operating income of $130M and net income of $162M, compared with operating and net losses of $260M and $200M, respectively, in the prior-year quarter.
The improvement was helped by revenue growth and a substantial reduction in research and development spending. R&D expense fell 27% to $583M as late-stage infectious-disease studies were completed or wound down, alongside broader cost-efficiency measures. SG&A rose 5% to $282M as Moderna continued commercial investment, though spending growth remained modest relative to revenue growth.
Cost of sales rose 54% to $318M, faster than revenue growth, due to higher product volume and manufacturing-related costs. Cost of sales represented about 24% of quarterly revenue, according to management. The company continues to expect gross-margin improvement in 2026 excluding its litigation-related charge, but the reported full-year cost-of-sales outlook still includes a $900M non-recurring litigation settlement charge.
The profitability improvement should also be viewed in the context of reduced R&D. The quarter demonstrates that Moderna can reach profitability at a stronger seasonal revenue level while spending less on infectious-disease trials. The central question is whether it can sustain this financial discipline while funding oncology, rare-disease development and the commercial launch requirements of a broader product portfolio.
Demand, Customers and Pricing
Management characterized U.S. seasonal respiratory demand as healthy but not uniformly strong across products. Through late October, approximately 44.1 million flu, COVID-19 and RSV vaccinations had been administered across retail and long-term-care channels, up 3% from the comparable period last year.
Flu vaccinations were running slightly ahead of the prior year, while COVID vaccinations were modestly behind. Management said October momentum suggested COVID vaccinations could finish roughly flat year over year in those channels. This supports the company’s raised 2026 outlook, but it does not point to a major expansion in underlying U.S. COVID vaccine utilization.
International demand and government arrangements were more important to the quarter. Moderna signed a five-year agreement with a local manufacturer in Mexico to support COVID vaccine supply, adding another international partnership to its commercial network. Management said international vaccination rates have stabilized and that Moderna has gained some share in certain markets, although it did not quantify either factor.
Pricing was not discussed in detail. Moderna also did not provide a price framework for intismeran, saying it is premature while regulatory submission work continues. Management said future pricing would be based on the value the therapy provides to health systems.
What is Moderna’s guidance for 2026?
Moderna raised its 2026 total revenue outlook to growth of 15% to 25%, compared with its previous expectation of growth of up to 10%. Management continues to expect revenue to be split approximately evenly between U.S. and international markets for the full year.
The company expects:
- Cost of sales of approximately $1.7B, including a previously announced $900M non-recurring litigation settlement charge.
- R&D expense of approximately $2.7B, reduced from the previous outlook of about $2.9B.
- SG&A expense of approximately $1.0B, unchanged from the prior forecast.
- Total GAAP operating expenses of approximately $4.5B excluding the $900M litigation charge, a $200M improvement from the earlier framework.
- Cash costs of approximately $3.8B, excluding stock-based compensation, depreciation and amortization, also a $200M improvement.
- Capital expenditures of approximately $0.2B, improved from a prior range of $0.2B to $0.3B.
- Year-end cash and investments of approximately $8.1B to $8.3B, including proceeds from the convertible-notes financing.
Management said the year-end cash outlook would be $5.5B to $5.7B excluding the $2.6B in net proceeds from the convertible offering and related capped-call transactions. The framework also assumes no additional borrowing under the approximately $900M remaining credit facility.
Balance Sheet, Cash Flow and Capital
Moderna ended September with $8.0B of cash, cash equivalents and investments, up from $6.9B at the end of the second quarter. The increase was largely financing-driven: the company issued approximately $3.0B in convertible senior notes and received approximately $2.6B in net proceeds after capped-call purchases and fees.
The financing materially improves liquidity, particularly as Moderna funds oncology development and prepares for potential commercialization of intismeran. But it also changes the capital structure. Convertible notes totaled $3.0B at quarter-end, alongside $591M of long-term debt.
Operating cash flow remains negative. Moderna used $2.715B in operating activities during the first nine months of 2026, though this was slightly improved from $2.803B used in the same period of 2025. Accounts receivable increased to $1.367B from $184M at year-end, reflecting seasonal product sales that had largely not been collected by quarter-end.
The company also made a $950M litigation settlement payment during the quarter. While the cash position is now stronger, the improvement should not be viewed solely as operating progress because the convertible financing supplied most of the quarter-over-quarter increase in cash and investments.
What Investors Should Watch
1. Fourth-Quarter COVID Vaccine Revenue
The raised revenue outlook reflects a stronger start to the season, but shipment timing benefited the third quarter. Fourth-quarter revenue will help clarify whether Moderna’s growth is being driven by sustainable demand, contract deliveries or the timing of seasonal vaccine distribution.
2. International Partnership Durability
Management said strategic partnerships account for more than half of international revenue. Investors should watch renewal activity, additional country agreements and the conversion of these arrangements into recurring seasonal demand, particularly as international markets become a larger share of Moderna’s commercial base.
3. Progress of mFLUSIVA and the Flu/COVID Combination Vaccine
mFLUSIVA’s first U.S. launch is limited because approval came after the contracting cycle. The pace of contracting and adoption for the 2027-2028 season will be more important than initial 2026 revenue. Regulatory progress for mCOMBRIAX in the United States could also determine whether Moderna can offer a more differentiated respiratory portfolio.
4. Intismeran Regulatory Submission and Manufacturing Readiness
The Phase 3 melanoma data established a meaningful clinical opportunity, but commercial value depends on regulatory review, manufacturing execution and reimbursement. Moderna and Merck are targeting a submission this year, while management hopes for approval next year if the review proceeds favorably.
5. Next Oncology and Rare-Disease Readouts
The upcoming event-driven Phase 2 renal cell carcinoma readout, propionic acidemia registrational data and initial mRNA-2808 results in multiple myeloma will test whether Moderna’s pipeline can extend beyond the melanoma program. Management said the renal cell carcinoma study could read out late this year or early next year, depending on event accumulation.
AlgovestIQ Takeaway
Moderna’s third quarter was materially stronger than the prior year, with 29% revenue growth, a return to GAAP profitability and a meaningful increase in its 2026 outlook. The financial improvement came from higher COVID vaccine sales, especially internationally, combined with lower R&D spending as certain infectious-disease programs wound down.
The raised outlook improves the near-term earnings profile, but the quality of growth warrants attention. COVID vaccines remain the dominant revenue driver, and some third-quarter upside reflected shipment timing. Meanwhile, mFLUSIVA is too early in its launch cycle to materially diversify revenue this year, and the U.S. path for the flu/COVID combination vaccine remains unresolved.
The balance sheet is stronger, but primarily because Moderna raised $3.0B of convertible debt. The financing gives the company flexibility to develop and potentially launch oncology assets, yet operating cash flow remained negative through the first nine months and receivables rose sharply during the seasonal selling period.
The most important development is intismeran. The melanoma data support a potentially significant new oncology franchise and provide evidence that Moderna’s platform may extend into individualized cancer therapy. Still, the investment case now depends on whether the company and Merck can translate clinical efficacy into regulatory approval, scalable manufacturing, reimbursement and adoption.
Evidence of durable international vaccine revenue, a successful commercial ramp for flu products, and continued positive oncology readouts would strengthen the diversification thesis. Conversely, weaker post-season COVID sales, delays in combination-vaccine regulation, or setbacks in the next intismeran studies would underscore Moderna’s continuing dependence on a concentrated respiratory-vaccine business.
How did MRNA stock react?
MRNA closed at $254.19 on Nov 6, 2026, up 5.3% from $241.46 on Nov 5, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 5, 2026 (before release) | $241.46 | — |
| Nov 6, 2026 | $254.19 | +5.3% |
| Nov 9, 2026 | $269.00 | +11.4% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- SRPTSarepta Therapeutics Q3 2026 Earnings: PMO Strength Offsets a Stabilized but Smaller ELEVIDYS BusinessNov 5, 2026
- BNTXBioNTech Q3 2026 Earnings: BMS Collaboration Revenue Lifts Quarter as Oncology Pipeline Takes Center StageNov 3, 2026
- RXRXRecursion Q3 2026 Earnings: Clinical Progress and Financing Extend Runway Into 2029Nov 3, 2026
- RAREUltragenyx Q3 2026 Earnings: Cost Reset and Gene-Therapy Launches Put 2027 Profitability in FocusNov 3, 2026
- VRTXVertex Q3 2026 Earnings: Revenue Growth Holds as Crinetics Acquisition Reshapes the Cost BaseNov 2, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Moderna Q3 FY2026 earnings call transcript, as of Nov 6, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Moderna Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 6, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 6, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.